Trial results reveal that long-acting injectable cabotegravir as PrEP is highly effective in preventing HIV acquisition in women - World Health Organization

1. Trial results reveal that long-acting injectable cabotegravir as PrEP is highly effective in preventing HIV acquisition in women  World Health Organization
2. Study finds long-acting shot helps women avoid HIV infection  The Associated Press
3. HIV Prevention Investigational Therapy Superior Vs Standard of Care  Contagionlive.com
4. HPTN 084 Study Update Press Briefing - Monday, 9 November 2020  HIV Prevention Trials Network
5. ViiV Healthcare's cabotegravir meets primary endpoint in HIV trial  Clinical Trials Arena
6. View Full Coverage on Google News

(CLICK HERE TO READ AND SEE MORE)